Third Rock Ventures Launches Tango Therapeutics with $55 Million Series A Investment

Company targeting context-dependent vulnerabilities in cancers for patients without effective treatment options

CAMBRIDGE, Mass., March 30, 2017 – Third Rock Ventures, LLC today announced the launch of Tango Therapeutics, a new cancer therapeutics company discovering and developing novel medicines designed to target cancer vulnerabilities beyond mutated oncogenes to deliver transformational new therapies for patients.